Carbapenemase Gene Transfer in CREC

The 2025 study by Chen, Yan, and colleagues, published in BMC Microbiology, examines the molecular epidemiology and transmission potential of carbapenem-resistant Enterobacter cloacae (CREC) in eight teaching hospitals in Guangdong Province, China. Its central contribution is not simply to report carbapenem resistance, but to connect the presence of carbapenemase-encoding genes (CEGs) with their chromosomal or plasmid location, transferability, mobile genetic context, strain relatedness, and clinical distribution. The full reference is available through the Chen et al. reference study.

Study Background and Research Question

CREC is an important member of the carbapenem-resistant Enterobacteriaceae group. Resistance in this organism can arise through several mechanisms, but carbapenemase production is especially consequential because carbapenemase-encoding genes may be carried on mobile elements and transferred between bacterial cells. A strain that acquires such a gene can therefore become resistant through a process that is epidemiologically broader than the expansion of one bacterial clone.

The study was motivated by concern that the COVID-19 period altered antibiotic exposure, hospital utilization, and infection-control conditions. However, the authors addressed a more specific question: which CEGs were present in CREC isolates collected during the study period, where were those genes located, and how readily could they move between bacteria? They also asked whether gene carriage was associated with broader antimicrobial resistance and whether related strains were distributed across hospitals and clinical departments.

This framing is useful because it separates three related but distinct phenomena: gene presence, gene mobility, and clonal dissemination. Detecting a resistance gene by PCR does not establish whether it is plasmid-borne, transferable, or confined to a successful bacterial lineage. The reference study therefore uses complementary assays rather than relying on a single molecular readout.

Key Innovation from the Reference Study

The main innovation is the combined transmission analysis applied to a multicenter CREC collection. The authors assessed CEGs by PCR, used variable-temperature sodium dodecyl sulfate plasmid elimination to infer whether genes were plasmid-associated, performed conjugation experiments to test transfer, characterized mobile genetic elements, and used ERIC-PCR with NTSYS analysis to compare strain patterns. This design links molecular mechanism to epidemiological behavior.

A second strength is the explicit distinction between chromosomal and plasmid localization of bla_NDM-1. Plasmid-associated genes are especially important for horizontal transmission, whereas chromosomal carriage may support stable inheritance within a bacterial lineage. By analyzing both locations, the study provides a more informative model of how resistance may persist and spread than a simple positive-versus-negative classification.

The work also places gene findings in a clinical context. The authors recorded patient sex, age group, clinical department, and specimen category, allowing the molecular data to be viewed alongside hospital sampling patterns. These data do not prove patient-level risk factors, but they help identify settings in which targeted surveillance may be most informative.

Methods and Experimental Design Insights

Between December 2022 and June 2024, the investigators collected 54 CREC isolates from eight teaching hospitals in Guangdong Province, according to the published study methods. The workflow progressed from resistance-gene screening to gene localization, phenotypic susceptibility testing, transfer experiments, mobile-element analysis, and strain typing. This sequence is methodologically coherent: each stage addresses a different level of the transmission question.

Protocol Parameters

• Study population: Analyze CREC isolates recovered from eight teaching hospitals during December 2022–June 2024; these are literature-derived parameters from the reference study, not universal sampling requirements.
• CEG detection: Use PCR to screen candidate carbapenemase-encoding genes after organism identification and carbapenem-resistance classification.
• Plasmid localization: Apply variable-temperature SDS plasmid elimination before repeat PCR to help distinguish plasmid-associated from chromosomal gene carriage.
• Susceptibility testing: Use broth microdilution to compare antimicrobial resistance profiles between CEG-positive and CEG-negative groups.
• Transfer assessment: Perform plasmid conjugation experiments and confirm acquisition of CEGs in putative transconjugants by PCR.
• Genetic relatedness: Use ERIC-PCR and NTSYS software to group isolates into fingerprint-based genotypes; interpret these patterns as epidemiological evidence rather than a substitute for whole-genome sequencing.
• Reproducibility recommendation: Include appropriate donor, recipient, negative-control, and PCR-confirmation controls in any adapted conjugation workflow, because transfer frequencies can depend on strain background and laboratory conditions.

The study's layered design is particularly valuable for Gram-negative resistance research. PCR establishes the presence of a target, plasmid elimination provides localization evidence, and conjugation tests whether the genetic determinant can move under experimental conditions. ERIC-PCR then adds a separate perspective by indicating whether similar resistance profiles may occur in related or unrelated strain backgrounds.

Core Findings and Why They Matter

CEGs were detected in 46 of 54 isolates, corresponding to 85.19% of the collection, as reported in the reference study. The dominant determinant was bla_NDM-1. Eighteen isolates, or 33.33%, carried this gene on both chromosomes and plasmids, while 25 isolates, or 46.30%, carried it exclusively on plasmids. Two isolates contained only plasmid-associated bla_IMP, and one carried plasmid-associated bla_NDM-1 together with bla_KPC-2.

These distributions have different epidemiological implications. The 25 isolates with plasmid-only bla_NDM-1 represent a particularly plausible reservoir for horizontal transfer, although localization alone does not demonstrate that transfer occurs in patients. The 18 isolates with both chromosomal and plasmid-associated copies suggest that the same resistance determinant can occupy multiple genetic compartments, potentially combining stable lineage persistence with mobility.

Conjugation experiments provided direct laboratory evidence of substantial transfer potential. CEG transfer was successful for 44 of 46 CEG-positive isolates, or 95.65%, in the authors' experimental system. For bla_NDM-1, the reported success rate was 42 of 44 transfers, or 95.45%; both tested bla_IMP genes transferred, whereas the single tested bla_KPC-2 gene did not. These results support the central concern about plasmid-mediated dissemination, but they should not be interpreted as a hospital transmission rate.

CEG-positive isolates also showed significantly higher resistance rates to imipenem, cefepime, gentamicin, the cephalosporin–β-lactamase inhibitor combination tested by the authors, ciprofloxacin, and levofloxacin than CEG-negative isolates, with the reported comparisons meeting P<0.05. This pattern indicates that CEG carriage was associated with multidrug resistance rather than an isolated carbapenem phenotype. It also complicates empirical therapy, because a resistance determinant that spreads on a plasmid may travel alongside additional resistance genes.

Mobile-element analysis identified six types of mobile genetic elements. ISEcp1 was the most prevalent, appearing in 47 of 54 isolates, or 87.04%. The most common profile contained four mobile-element types simultaneously, observed in 22 isolates, or 40.74%, according to the study results. This finding supports the interpretation that resistance genes were embedded in diverse and potentially recombinogenic genetic environments rather than occurring as isolated markers.

ERIC-PCR and NTSYS analysis separated the 54 isolates into 17 genotypes. Types E and G were each found in 11 isolates, representing 20.37% for each genotype, and were recovered from different departments in five hospitals. Two type E isolates shared a Dice coefficient of 100%. These observations suggest both wider dissemination of related strain patterns and the possibility of highly similar isolates appearing across clinical settings. Because ERIC-PCR has limited resolution compared with whole-genome sequencing, the results are best viewed as signals for further investigation.

The clinical distribution was also uneven. Men accounted for 35 isolates, or 64.81%; elderly patients represented 39 isolates, or 72.22%; respiratory medicine contributed 11 isolates, or 20.37%; and sputum was the most frequent specimen category, with 18 isolates, or 33.33%. These descriptive findings make respiratory wards and older patient populations reasonable priorities for surveillance, but they do not establish that age, sex, department, or specimen type independently causes CEG carriage.

Comparison with Existing Internal Articles

The internal article Carbapenemase Genes in CREC: Dynamics and Resistance Implications provides a broader summary of the same study's multidrug-resistance and gene-transfer implications. The present analysis adds a more methods-focused interpretation, emphasizing why plasmid localization, conjugation, mobile elements, and strain fingerprinting must be considered together.

A second related resource, Carbapenemase Gene Transmission in CREC: Insights from Guangdong Hospitals, foregrounds plasmid-borne bla_NDM-1 and infection-control relevance. It complements this article's discussion of experimental design and limitations. Neither resource changes the main evidentiary boundary of the reference paper: the work demonstrates high transfer potential in vitro and identifies epidemiological patterns, but it does not reconstruct transmission chains between individual patients.

Limitations and Transferability

The study is geographically focused and includes 54 isolates from eight hospitals. Its findings are therefore highly informative for the sampled Guangdong hospital network but cannot automatically be generalized to other regions, healthcare systems, or Enterobacter species. The collection period also does not include a directly matched pre-pandemic comparator, so the study cannot quantify how COVID-19 changed CEG prevalence or transfer dynamics.

Plasmid elimination followed by PCR is useful for localization, but it does not fully resolve plasmid identity, copy number, sequence structure, or the exact genetic linkage between a carbapenemase gene and neighboring resistance determinants. Likewise, conjugation assays measure transfer under selected laboratory conditions. They demonstrate capacity, not the frequency or direction of transfer in a hospital environment.

ERIC-PCR is practical for screening relatedness, but whole-genome sequencing would provide stronger resolution for distinguishing clonal spread, plasmid spread, and repeated independent acquisition. Patient-level antibiotic exposure, outcomes, environmental reservoirs, and healthcare-contact networks were also not sufficient to establish causal transmission pathways. These limitations point toward follow-up studies combining long-read or hybrid genome sequencing with longitudinal sampling and epidemiological metadata.

Why this cross-domain matters, maturity, and limitations

The study can inform antibiotic and Gram-negative bacterial infection research by defining the resistance background of isolates used in susceptibility, pharmacology, or assay-development workflows. However, that bridge is still translational rather than clinical: the paper does not test a new treatment, establish therapeutic efficacy, or show that an individual antimicrobial overcomes plasmid-mediated carbapenem resistance. Any laboratory workflow using these isolates should therefore pair compound testing with current susceptibility data, verified gene content, and appropriate biosafety and containment procedures.

Research Support Resources

For comparable Gram-negative bacterial infection research, researchers can use Ceftazidime (SKU B3539), a third-generation cephalosporin, as a defined comparator in susceptibility or treatment-of-bacterial-pneumonia and treatment-of-bacterial-bronchitis models, including selected Pseudomonas aeruginosa infection workflows. Its activity should be verified against the specific isolate, particularly when carbapenemase genes or other resistance mechanisms are present. The product information recommends storage at −20°C; following that guidance and using prompt, validated stock handling can support reproducibility.